C
ALLO icon

Covestor’s Allogene Therapeutics ALLO Stock Holding History

Covestor’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
121
+85
+236% +$187 ﹤0.01% 2457
2026
Q1 		$0 Hold
36
– – ﹤0.01% 2211
2025
Q4 		$0 Hold
36
– – ﹤0.01% 2224
2025
Q3 		$0 Hold
36
– – ﹤0.01% 2235
2025
Q2 		$0 Sell
36
-3
-8% -$4 ﹤0.01% 2157
2025
Q1 		$0 Buy
39
+1
+3% +$2 ﹤0.01% 2165
2024
Q4 		$0 Buy
38
+20
+111% +$49 ﹤0.01% 2186
2024
Q3 		$0 Sell
18
-1
-5% -$3 ﹤0.01% 2163
2024
Q2 		$0 Hold
19
– – ﹤0.01% 2194
2024
Q1 		$0 Sell
19
-1
-5% -$4 ﹤0.01% 2192
2023
Q4 		$0 Sell
20
-2
-9% -$6 ﹤0.01% 2096
2023
Q3 		$0 Sell
22
-3
-12% -$13 ﹤0.01% 2064
2023
Q2 		$0 Buy
25
+12
+92% +$65 ﹤0.01% 2083
2023
Q1 		$0 Hold
13
– – ﹤0.01% 1963
2022
Q4 		$0 Sell
13
-1
-7% -$9 ﹤0.01% 2008
2022
Q3 		$0 Sell
14
-8
-36% -$109 ﹤0.01% 1929
2022
Q2 		$0 Sell
22
-6
-21% -$53 ﹤0.01% 1859
2022
Q1 		$0 Sell
28
-6
-18% -$62 ﹤0.01% 2061
2021
Q4 		$1K Buy
+34
New +$600 ﹤0.01% 1615

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Covestor's ALLO Position: Q2 2026 in Review

Covestor increased its Allogene Therapeutics (ALLO) stake by 236% in Q2 2026, buying an estimated $187 and bringing the position to 121 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2457.

Covestor first reported a position in ALLO in Q4 2021 and has held it in 19 quarters since. The position peaked at $1K in Q4 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Covestor held 121 shares of Allogene Therapeutics worth $0 as of Q2 2026.
  • Covestor bought 85 Allogene Therapeutics shares in Q2 2026, an estimated $187.
  • Allogene Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2457 holding.
  • Covestor first reported a position in Allogene Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Allogene Therapeutics position peaked at $1K in Q4 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.